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Autoantibodies are found in most patients with polymyositis (PM) or dermatomyositis (DM) and 35–40% of these patients have
myositis-specific antibodies. Twenty-five to thirty percent have anti-aminoacyl-tRNA synthetases, of which anti-Jo-1, directed at
histidyl-tRNA synthetase, is by far the most common. Patients with anti-synthetases have a high frequency of myositis,
interstitial lung disease, Raynaud’s phenomenon, and other features constituting an ‘‘anti-synthetase syndrome.’’ Anti-
synthetases tend to react with conformational epitopes and to inhibit enzymatic activity, suggesting reaction with conserved
regions. Sera with antibodies to alanyl-tRNA synthetase (anti–PL-12) also have antibodies to tRNAa1a, whereas most sera with
other anti-synthetases do not react directly with tRNA. Production of the antibodies appears to be antigen-driven, and is
influenced by HLA genes, although an initiating factor, possibly a viral infection, may be important. Antibodies to other
cytoplasmic antigens, most notably the signal recognition particle (anti-SRP), are seen in a small percentage of patients. Patients
with anti-SRP do not tend to develop the antisynthetase syndrome, but may have very severe disease. Antibodies to the nuclear
antigen Mi-2 are also specific for myositis, and are strongly associated with DM. Several autoantibodies, including anti–PM-Scl,
anti-Ku, and anti-Ul and U2 RNP, have been associated with scleroderma-PM overlap. The role of humoral immunity in the
myositis of PM and DM has not yet been clarified. Capillary loss and ischemic damage are important in DM, and seem to be
mediated by humoral mechanisms, whereas cell-mediated attack on muscle fibers is important in PM. The mechanism of skin
injury in cutaneous lesions is not known, but antibody deposition is inconsistent and uncommon. Whether the myositis-
specific antibodies are involved in disease pathogenesis is not yet known, although there is no direct evidence for this. An
understanding of the reasons for production of these antibodies, however, should provide insight into the etiology and
pathogenesis of PM and DM. J Invest Dermatol 100:116S–123S, 1993
Polymyositis (PM) and dermatomyositis (DM) are idiopathic inflamma-
tory myopathies characterized by weakness and elevated muscle
enzymes [1]. Patients with DM have associated characteristic cutaneous
manifestations. The cause of these conditions is unknown, but there is
ample evidence of the involvement of autoimmunity in the myopathy [2].
Two lines of evidence have been pursued in recent years that have
greatly enhanced our understanding of the autoimmune response in PM/
DM. These include studies that have defined and characterized the
disease-specific autoantibodies in sera of myositis patients, and studies
characterizing the inflammatory infiltrates in myositis muscle [3].
HUMORAL VERSUS CELLULAR IMMUNITY IN MYOSITIS
There is increasing knowledge about the mechanism for muscle damage,
although there is less specific information about the underlying
mechanisms of cutaneous and other extra-muscle manifestations. The
operative processes in muscle damage may differ between PM and DM
[4]. Cell-mediated immunity appears to be a very important pathogenic
mechanism in PM, whereas humorally mediated damage to muscle
blood vessels seems to be more important in juvenile and adult DM.
However, humoral autoimmunity in the form of autoantibodies is
prominent in both conditions.
Arahata and Engel found that muscle biopsies from patients with adult
PM show many fibers that are surrounded and invaded by mononuclear
cells [5,6]. These fibers are intact, and therefore this cellular attack seems
to be a primary event, rather than a response to necrosis. Phenotypic
analysis of the cells that are surrounding and invading muscle fibers
indicates that most are T lymphocytes and many of them express CD8.
The proportion of CD8 þ cells is higher among invading than
surrounding cells. Other markers demonstrate that these surrounding
and invading cells are cytotoxic rather than suppressor cells [7], with
little involvement of killer (K) or natural killer (NK) cells. These are strong
indications that a T-cell–mediated, antigen-directed attack on muscle
occurs in PM and plays a major role in muscle cell damage. Similar
findings are seen in inclusion body myositis, another form of idiopathic
inflammatory myopathy.
A higher percentage of B cells is seen in DM. Very few surrounded
and invaded fibers are seen in DM, even fewer than are seen in
Duchenne’s muscular dystrophy [6]. This suggests that cell-mediated
immunity is not a major factor in DM, whereas other evidence supports a
major role for humoral immunity in DM. In many cases of adult DM and
almost all cases of juvenile DM, there is prominent evidence of
involvement of muscle blood vessels, with capillary loss and ischemic
muscle damage [1,4]. Endothelial cell abnormalities have frequently
been observed. Endothelial injury and capillary loss occur early in
disease, and have been demonstrated in biopsies from patients with DM
prior to other changes on light microscopy and prior to weakness [8].
Other evidence of vascular involvement in DM has been found.
Nailfold capillary abnormalities may be seen in DM, including bushy
capillaries, giant capillary loops, and other changes [9]. The pattern of
perifascicular atrophy of muscle fibers associated with PM/DM,
attributed to ischemic effects, is more common in DM than PM, and
especially common in juvenile DM. Inflammatory infiltrates often are
concentrated in the interstitial and perivascular areas [5].
The vessel injury in DM appears to be complement-mediated.
Deposition of the membrane attack complex of complement is
consistently seen in the muscle blood vessels in juvenile DM [10]. Such
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deposition is seen in adult DM as well, in almost 90% of cases in a recent
study [8], but it has not been reported in PM. Although this indicates that
complement is activated locally, it does not necessarily imply that it is a
primary event that plays a pathogenic role. However, Emslie-Smith and
Engel [8] reported that the deposition of membrane attack complex is a
very early finding in DM muscle and may occur prior to other observed
abnormalities on the muscle biopsy, which is consistent with a primary
role in muscle injury. They noted that in one case a patient who had not
yet become weak and whose muscle biopsy was normal by light
microscopy showed unusually extensive membrane attack complex
deposition in muscle vessels. The patient went on to develop over-
whelming, fatal DM.
The factors leading to local complement activation are not entirely
clear, because deposition of antibody in muscle vessels is not consistently
observed [11]. However, several studies have reported deposition of IgG
or IgM antibody in muscle vessels in at least some cases [12,13].
Consistent with the previous observations, deposition is observed more
frequently in DM than in PM, and more frequently in juvenile than in adult
DM. It is possible that antibody or immune complexes are able to activate
complement locally either without deposition of antibody or with release
of antibody, leading to the observations noted.
Despite these indications of a role for humoral immunity in the
muscle injury of DM, its role in the development of the skin
manifestations in DM is unclear. The similarities of the erythematous
or poikilodermatous lesions of DM to lupus suggest a possible role for
antibody. However, deposition of antibody in DM is inconsistent, and
deposition along the dermal-epidermal junction as is seen in lupus is very
uncommon [14].
AUTOANTIBODIES
Autoantibodies are an easily demonstrated and clear expression of
autoimmunity in PM/DM (Table I). Reichlin and Arnett [15] were able to
demonstrate autoantibodies to nuclear or cytoplasmic cellular antigens in
almost 90% of PM/DM patients, indicating that they are very common.
Autoantibodies of defined specificity are found in approximately 45–55% of
adults and a small percentage of children. Others have autoantibodies
detected by screening tests, such as indirect immunofluoresence, but are
negative for recognized antibody specificities. Approximately 35–40% of
PM/DM patients have ‘‘myositis-specific autoantibodies’’ (MSA) [16].
Almost all patients with MSA have myositis, either alone or as part of
overlap syndromes. It is rare for an individual patient to have more than one
MSA. Generally, particular MSA have been associated with characteristic
clinical features, so that the MSA tend to mark clinical subgroups. One
antibody, and–56 kD, is an exception to these rules, having been reported
in a high percentage of all patients, including a high percentage of children
[17]. About 25% of PM/DM patients has defined autoantibodies that are not
MSA, antibodies that have been associated with other connective tissue
diseases, such as anti-U1RNP or anti-Ro/SSA. These antibodies may occur
alone or in association with any of the MSA.
Any possible role of these antibodies in disease pathogenesis remains
speculative, even in patients whose muscle injury appears to be
humorally mediated. There has been no evidence that it is the MSA
that locally activate complement in DM resulting in vessel damage. In
fact, the MSA are least common in juvenile DM, the condition in which
the evidence is strongest for the importance of a humorally mediated
vasculopathy. However, a pathogenetic role has not been excluded. The
MSA are of great interest because of their potential value as clues to
cause as well as their possible use in diagnosis and patient classification.
ANTI-SYNTHETASES
The autoantibodies that are most common as a group and the best studied
among the MSA are those that react with the aminoacyl-tRNA
synthetases. These cytoplasmic enzymes catalyze the binding of an
amino acid to its specific transfer RNA (tRNA) for transport to the
ribosome and incorporation into a growing polypeptide chain during
protein synthesis [18]. The most common anti-synthetase, anti-Jo-1, reacts
with histidyl-tRNA synthetase (hisRS) [19,20]. Four other anti-synthetase
autoantibodies have been identified, reacting with synthetases for
threonine (thrRS), alanine (alaRS), glycine (glyRS), and isoleucine (ileRS)
[21–23]. The relative frequencies of these four non-Jo-1 anti-synthetases
vary in different studies, possibly reflecting differences among populations.
Anti-Jo-1 appears to be about 5–10 times as common as any one of the
four, and about 2–4 times as common as all four together.
Each of the 20 enzymes that performs this function for a particular
amino acid must accurately recognize the specific tRNA for its amino
acid to maintain fidelity of translation, thus requiring a ‘‘second genetic
code’’ on the tRNA that is only now being deciphered [24]. Each enzyme
is therefore different, distinctive on the molecular and the antigenic level.
Each anti-synthetase recognizes only a single synthetase, and no serum
has been reported to have more than one of the five anti-synthetases. This
is remarkable considering the similarity of the five anti-synthetases in
their clinical associations.
Clinical Picture Anti-synthetases have been found in both adult PM and
adult DM, as well as in some patients with overlap syndromes that
involve myositis. The presence of these biologic markers in both PM and
DM suggests that at least some cases of PM and DM may have similar
origins despite their apparent differences in pathogenesis. Among
patients with anti-Jo-1, PM is 2–10 times more common than DM
[25,26], but among patients with other anti-synthetases, PM is less
predominant [27,28], and may be less frequent than DM [16]. DM was
seen in five of six patients with anti-EJ (anti-glyRS) antibodies [29].
The myositis of patients with anti-synthetases is clinically similar to
that of patients without the antibodies. However, recent studies have
indicated that patients with anti-synthetases may respond less completely
to treatment than others with myositis [16], and more often have
recurrences as treatment is withdrawn.
Other features that have been associated with anti-synthetases make
these patients distinctive enough among myositis patients to be
designated as having an ‘‘anti-synthetase syndrome.’’ The most
distinguishing feature is the very high frequency of interstitial lung
disease (ILD), found in at least 50–75% of those with anti-synthetases
compared to 10–20% of others with myositis [26,27,30,31]. Although
ILD can be asymptomatic, it also can be severe or fatal. Some patients
with each of the anti-synthetases have had ILD as the predominant
clinical problem, occasionally without evident associated myositis [27],
An increased frequency of arthritis (490%) and Raynaud’s phenomenon
(60%) has also been associated with anti-synthetases [16]. In patients
with anti-synthetases, the arthritis may be more severe and may be
deforming, a manifestation not usually seen in other myositis patients
without overlap [32]. An interesting cutaneous feature is ‘‘mechanic’s
hands,’’ which is marked by hy-perkeratosis with fissuring and
hyperpigmentation along the radial and palmar aspects of the fingers,
appearing as dirty horizontal lines. First described in association with
connective tissue diseases and Raynaud’s phenomenon [33], it was
recently found to be associated with anti-synthetases [16].
Immunologic Aspects The anti-synthetases have many interesting
features. Almost every serum with any of the anti-synthetases inhibits
the antigenic enzyme specifically, without affecting activity of other
synthetases [19]. This inhibitory activity is proportional to the amount of
antibody [25]. It is noteworthy because inhibition of the antigen is not
consistently seen with animal antisera to these enzymes. Some animal
antisera resulting from immunization with purified synthetases have
specifically inhibited the antigenic enzyme whereas others have not
[34–36]. The consistent inhibition by the autoantibodies suggests
reactivity with active regions of the enzyme that tends to be highly
conserved, areas usually spared when an animal is immunized with a
protein from another species. Inhibition of the functional activity of the
antigen is a characteristic observed with other autoantibodies tested,
including the anti-mitochondrial antibodies of primary biliary cirrhosis,
the antibodies to the U small nuclear ribonucleoproteins (RNPs) in lupus
and overlap syndromes, and others.
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In immunoprecipitation studies, a restricted pattern of tRNA is always
found associated with the antigenic enzymes that is characteristic for the
particular anti-synthetase. The tRNA immunoprecipitated by and–Jo-1
(anti-hisRS) has been sequenced and identified as a tRNA specific for
hisitidine (tRNAhis). The tRNA immunoprecipitated by anti–PL-12
(anti-alaRS) have also been found to be specific for the amino acid of
the associated antigenic synthetase (tRNAala) [22,37,38], and this is
presumed to be the case for the other anti-synthetases. In most
cases, deproteinized tRNA is not antigenic, whereas the enzyme protein
retains antigenicity despite removal of tRNA [21,23,37]. The enzyme
has affinity for the tRNA, which at least partially explains its presence in
the immunoprecipitate, but immunoprecipitation of tRNA is not
necessarily an expected property of an antibody to a synthetase
enzyme. Animal antisera to synthetases have generally not immunopre-
cipitated the cognate tRNA [21]. One implication of this is that the
autoantibodies of PM/DM may specifically spare the tRNA binding site.
This would be expected if the immunogen were the complex of
synthetase and RNA, as would be predicted by some hypotheses of
anti-synthetase development.
An exception to this pattern of restriction of antigenicity to the protein
is anti–PL-12. Although most sera with antibodies to other synthetases
(with some exceptions) do not react with deproteinized tRNA, most sera
with anti–PL-12 have both antibodies to the synthetase and antibodies to
tRNA for alanine (tRNAala), which can be separated from each other [22].
Anti-tRNAala could represent an anti-idiotypic response to the anti-alaRS
[22]. It has also been suggested that the anti-tRNAala may have been the
original antibody, possibly arising as an antibody to viral RNA, with anti-
alaRS developing as an anti-idiotype against the anti-tRNAala [22,39].
Anti-OJ (anti-ileRS) is of particular interest because, unlike the other
anti-synthetases that react with free, individual cytoplasmic proteins,
anti-OJ reacts with an enzyme that is a component of the multi-enzyme
synthetase complex [23,40]. In higher eukaryotes, eight of the
aminoacyl-tRNA synthetases are found complexed together, along with
additional non-synthetase proteins. Anti-OJ immunoprecipitates this
entire complex, but only a very limited set of tRNA [23], At 150 kD,
ileRS is the second largest complex component. Most sera with anti-OJ
consistently and specifically inhibit ileRS activity almost completely,
suggesting that despite immunoprecipitation of the entire complex, ileRS
is the main antigen. Certain sera also show evidence of reactivity with
other components of the complex (other synthetases) in addition to ileRS,
including lysyl, glutaminyl, and/or leucyl-tRNA synthetases. These sera
show the same tRNA immunoprecipitation pattern as other anti-OJ sera
[40]. This is the only situation in which reaction of a single serum with
more than one synthetase is seen, and it is restricted to other synthetases
that are complexed to the main antigen.
The anti-synthetases appear to react primarily with conformational
epitopes. This was demonstrated for anti–PL-7 (anti-thrRS) by showing
that it does not react by immunoblot despite strong reactivity in
immunoprecipitation [34]. In comparison, animal sera raised against
thrRS react well by immunoblot. Although most anti–Jo-1 autoimmune
sera react well by immunoblot, this may not represent reaction with strict
linear epitopes. When tested systematically by epitope scanning against
synthesized sequential hexapeptides of the entire Jo-1 amino acid
sequence, no anti–Jo-1 sera reacted with any peptides, whereas animal
antisera showed strong reactivity with peptides throughout the sequence
[35]. Anti-OJ also does not usually react with ileRS in immunoblot [40].
Study of anti–Jo-1 epitopes using proteolytic hisRS fragments appears to
indicate similar or shared epitopes recognized in immunoblot [41].
Further study using recombinant mutant forms of hisRS also indicates
similarity in immunoblot epitopes, and some similarities in conforma-
tional epitopes recognized in immunoprecipitation [42]. The latter study
also indicated that some differences between sera could be detected, and
that sera reacted with multiple epitopes. This would be consistent with a
scenario in which reaction with one epitope results from a common
initiating event, followed by an expansion of the reaction against the
antigenic molecule itself [43].
More direct evidence that the anti-Jo-1 response is antigen driven
comes from recent studies of Miller et al [35]. In one case in which serial
serum samples over time were available beginning prior to the
development of anti–Jo-1, the antibody was observed to develop several
months prior to the onset of myositis. Initial sera showed predominance
of IgM, but in later samples IgM anti-Jo-1 fell and IgG titers rose,
demonstrating an isotype switch that is typical of an immunization. In
addition, antibody affinity for the Jo-1 antigen increased over this period.
Affinity maturation toward the recognized antigen strongly suggests that
that antigen is the target and is driving the response.
Even if the anti-Jo-1 response is antigen driven, the patient’s hisRS is
not necessarily the original immunogen. Because different anti-synthe-
tases are targeted by different PM/DM patients with a similar syndrome,
these antibodies pose the crucial question of why the synthetase enzymes
were selected as antigens in this disease. An aspect of the synthetase
function may be important. The anti-synthetases are directed at an
enzyme family that shares an analogous function, but structural
relatedness is limited. Some general similarities have been identified
between sequences and structures of the bacterial forms of the enzymes
that allow the separation of two general classes of synthetases [44], but
no cross-reactivity with multiple synthetases is seen either by auto-
antibodies or animal antisera. This raises the possibility that the antigens
were selected because of their function, suggesting that the antigens are
the intended target.
The important features of synthetases leading to their antigenicity in
myositis are not clear. Binding of tRNA by synthetases has been
suggested as a possibly important factor leading to the development of
these autoantibodies. Nucleic acid binding is a feature of several
autoantigens in systemic autoimmune diseases, such as Ro/SSA, La/SSB,
U1RNP and other small nuclear ribonucleoproteins, and others. The
presence of the synthetases in the cytoplasm has also been suggested as a
possibly important factor. Antibodies to cytoplasmic antigens are
relatively common in myositis, being present in 21% of patients by
indirect immunofluorescence [15]. There may be an association of
myositis with antibodies to cytoplasmic antigens, or possibly antigens
involved in protein synthesis [19,45]. It may be possible to get a clue to
the important features of the antigens that initiate these responses by
looking at other proteins that can be antigenic in myositis besides
synthetases, particularly when features of the anti-synthetase syndrome
are seen.
OTHER ANTI-CYTOPLASMIC ANTIBODIES
Autoantibodies to specific cytoplasmic proteins other than synthetases
are found in a very small number of PM/DM patients, but a variety of
such antibodies has been seen. The most important appears to be anti-
signal recognition particle (SRP), which was estimated to occur in about
4% of PM/DM patients [46]. It reacts with the SRP, which consists of at
least six proteins (72, 68, 54, 19, 14, and 9 kD) and a 7S RNA labeled
7SL. The SRP functions in the translocation of newly formed secretory or
membrane proteins into the endoplasmic reticulum by binding to the
signal sequence of the nascent polypeptide chain through its 54-kD
protein. The 54-kD protein is the major antigen for autoantibodies as
determined by immunoblotting studies, in which the 54-kD protein
reacts with almost all anti-SRP sera, and immunoprecipitation, in which
the 54-kD protein is usually the most prominent band. Some sera also
react with the 68- and/or the 72-kD proteins, usually in addition to the
54 kD. Thus far, no sera have been found to react directly with the 7SL
RNA, although as part of the particle, it is incorporated into the
immunoprecipitate and helps identify the antibody.
Anti-SRP is strongly associated with PM. In our recent series, all 12
patients with the antibody had PM without the DM rash [46]. The clinical
subgroup of PM patients that is marked by anti-SRP differs significantly
from the group marked by anti-synthetases. The frequency of ILD has
been much lower, at about 10%, comparable to PM patients without
anti-synthetases. Arthritis and Ray-naud’s phenomenon are also uncom-
mon. However, unlike PM patients without anti-SRP or anti-synthetases,
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many of the patients with anti-SRP had a very severe course and were
very resistant to therapy [46]. The anti-SRP subgroup and other antibody-
determined subgroups may have clearcut clinical differences from each
other, and from PM/DM overall [16]. The antibodies can therefore be
clinically useful in patient characterization and prognosis. These
differences also suggest the possibility of significant differences in
pathogenetic and/or etiologic factors.
As noted, immunoprecipitation of specific tRNA, a particular property
of the autoantibodies, suggests that tRNA binding may be an important
feature leading to immunogenicity of these proteins. Two autoantibodies
that immunoprecipitate tRNA, but are not anti-synthetases, have been
found in myositis: anti-Fer and anti-Mas [47]. Both occur in very low
frequency (o1%), but anti-Mas is more common than anti-Fer. Anti-Fer
appears to react with eukaryotic elongation factor 1a [48], a 48-kD
translation factor that has affinity for aminoacylated tRNA. The antibody
immunoprecipitates heterogeneous tRNA that appears to contain all
forms of tRNA, as might be expected because elongation factor la can
bind to aminoacylated tRNA non-specifically. The antibody does not
react in im-munoblot, indicating exclusive reactivity with conformational
epitope(s), but at least one epitope is highly conserved. This antibody has
been found in only one patient with localized nodular myositis and has
not been associated with the anti-synthetase syndrome. Anti-Mas
immunoprecipitates a small RNA that appears to be a tRNA, but no
associated protein has been found [47]. Among a large series of patients,
two were found to have anti-Mas, and both were similar in their history of
alcohol-related rhabdomyolysis prior to the development of PM, in their
history of diabetes, and in their HLA type (DR4, DRw53) [16]. However,
the anti-synthetase syndrome has not been found with anti-Mas. Also, it
should be noted that antibodies to tRNA-related antigens may occur in
other conditions, such as anti-Wa, which is associated with scleroderma
[49], or antibody to initiator methionine tRNA, which has been
associated with Sjo¨gren’s syndrome [50]. Thus, an association with
tRNA may not be the common factor in development of these antibodies.
Although antibodies to tRNA-related proteins other than anti-synthe-
tases have not been associated with the anti-synthetase syndrome,
antibodies to a protein involved in protein synthesis and translation have
been associated with a picture that does look like the anti-synthetase
syndrome. Anti-KJ was found in two patients with PM, ILD, and Raynaud’s
phenomenon [45]. The antigen has not yet been identified, but it was
determined to be a translation-related protein, because IgG from the two
patients inhibited translation of globin messenger RNA in vitro. The
antigen did not appear to be a tRNA-related protein because no tRNA was
immunoprecipi-tated, nor was it a synthetase, because none was inhibited
despite the inhibition of translation. Preliminary evidence indicates that
there is at least one other antibody to a non-tRNA-related translation
factor, in addition to anti-KJ, that can be associated with PM with ILD.
Thus, a relationship to translation and protein synthesis may be an
important factor in initiation of these responses.
Various hypotheses have been suggested to explain how these
properties might lead a protein to become antigenic [2,51], particularly
the possibility that viral RNA or protein might share similar features to the
cellular proteins, with molecular mimicry leading to cross-reactive
antibodies. An alternative scenario would be an interaction of viral RNA
or protein with translation-related proteins (synthetases or factors) during
the course of infection leading to immunogenic complexes. Picorna-
viruses such as Coxsackie, which have been implicated as possible
initiating agents in myositis for other reasons [52], are RNA viruses with
the potential for such interactions.
AUTOANTIBODIES IN SCLERODERMA-POLYMYOSITIS
OVERLAP
Other autoantibodies are also important in PM/DM. Of particular interest
are autoantibodies associated with scleroderma-polymyositis overlap.
This combination is a fairly common form of overlap syndrome, and
autoantibodies are very common in these patients [53]. Certain
autoantibodies have been particularly associated with this overlap
syndrome, although most can also be seen in the absence of overlap.
The most common is anti-PM-Scl, which occurs in about 8% of all
myositis patients in the U.S. [54], and about 3% of scleroderma patients
[55]. Most patients with the antibody are adults, but it may occur in
children. It can be seen in PM/DM or scleroderma without overlap, but
overlap is seen in 50% or more of the patients with the antibody. Some
overlap patients have myositis early in their course that responds to
treatment, whereas scleroderma persists. Diffuse or limited cutaneous
scleroderma may occur with this antibody. Blaszczyk and colleagues
have reported that the scleroderma-myositis overlap syndrome that
occurs with anti-PM-Scl can be distinguished from other forms of
overlap, and have referred to it as ‘‘scleromyositis’’ [56,57]. Some of the
features of systemic scleroderma were not seen, and it was felt to have a
better prognosis.
Anti-PM-Scl reacts with an antigen in the nucleolus that may also be
present in the nucleus. In indirect immunofluorescence, a pattern of
intense nucleolar staining with significant nucleoplasmic staining is
usually seen, although nucleolar staining alone was seen with affinity-
purified anti-PM-Scl antibody [58]. Although PM/DM has been asso-
ciated with antibodies to cytoplasmic antigens as described above, a high
frequency and variety of anti-nucleolar antibodies have been associated
with scleroderma. The fact that anti-PM-Scl is associated with
scleroderma as well as myositis fits this pattern, and suggests a closer
association with the scleroderma antibodies. The antigen appears to be a
large complex of 11-16 proteins ranging from 20 kD to 110 kD, without
known associated nucleic acid [59,60]. Sera of almost all patients with
anti-PM-Scl react with a 100-kD protein, and about half also react with a
75-kD protein. The two proteins, which both appear to be part of the
complex, are antigenically distinct and have no amino acid sequence
homology [61,62]. This is another example of antibodies to more than
one component of the same complex, suggesting an antigen-driven
response, with the complex as antigen. No other component has yet been
determined to be antigenic. The sequence of the 75-kD protein actually
predicts a much smaller protein that migrates aberrantly on gels [61]. The
role of the PM-Scl complex in the cell is unknown, but it may be involved
in pre-ribosomal formation [59].
Anti-Ku has also been associated with scleroderma-polymyositis
overlap. It was first described in Japan [63], where it is found more
commonly among patients with this overlap syndrome than is anti–PM-
Scl [53], the latter being found predominantly in Caucasian patients.
Anti-Ku antibody, however, is also common in SLE without myositis,
particularly in patients with anti-Sm without anti-U1RNP [64], and
cannot be considered a myositis-specific antibody. Anti-Ku is unusual
among autoantibodies because of its relative species specificity, reacting
much better with human antigen than that of other species. In most cases
it reacts with conformational epitopes [65], and the areas of the protein
carrying several of the predominant epitopes have been shown to be
subject to evolutionary change by sequence analysis [66]. Despite being
originally described as a precipitin, most sera with anti-Ku do not show
precipitating antibodies in Ouchterlony immunodiffusion or counter-
immunoelectrophoresis against calf thymus extracts [64]. This may relate
to its species specificity. The Ku antigen is a complex of proteins of 70
and 80–86 kD that binds to free ends of DNA, without apparent regard for
the DNA sequence [67]. The role has not been determined, although it
has been suggested that it may be involved in DNA repair. Most anti-Ku
patient sera react with both proteins of Ku antigen in immunoblot.
Anti-UIRNP (antibody to the Ul small nuclear ribonucleopro-tein) is
common in patients with overlap syndromes involving myositis,
particularly those including systemic lupus erythematosus as in mixed
connective tissue disease, but also in patients with sclero-derma-
polymyositis overlap. Antibodies to the 68–70-kD protein have been
associated with myositis in some studies [68,69]. This protein has been
found to share short antigenic sequences with a murine retroviral gag
protein [43] and an influenza B virus protein [70], suggesting that it may
become antigenic through molecular mimicry. A much smaller
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percentage of patients has antibodies that react with U2RNP-specific
proteins [71]. Their sera usually have antibodies to the B00 protein, and
often also the A0 protein. Most sera with these antibodies also react with
U1RNP, often through a cross-reaction of the B00-U2RNP and A-U1RNP
proteins, although antibodies to other U1RNP proteins are also usually
seen. The most common clinical picture associated with anti-U2RNP has
been scleroderma-polymyositis overlap syndrome.
ANTI–Mi-2
Only one MSA, anti-Mi-2, has been specifically associated with DM as
opposed to PM [72]. Over 95% of patients with anti-Mi-2 have had the
DM rash [73]. This antibody is very strongly myositis-specific, being
found in only one patient without myositis, who had features of the DM
rash. In most patients with the antibody, the rash is florid and a prominent
part of their disease, although it may also be subtle or overlooked at first.
This myositis is usually more responsive and easier to treat than that
associated with anti-synthetases [16], although it can be very severe.
Generally, the features of the anti-synthetase syndrome have not been
more frequent in patients with anti-Mi-2 than in others with myositis.
Anti-Mi-2 may occur in juvenile DM, suggesting that at least some cases
of juvenile DM are similar to adult DM. This is in contrast to anti - Jo-1,
which, although more common than anti-Mi-2 overall, has not been seen
in juvenile DM. This further demonstrates the clinical significance of the
subgroups defined by the MSA.
Anti–Mi-2 may be detected by immunodiffusion and immunopreci-
pitation, but reactivity seems to be limited to conformational epitopes,
because immunoblotting has been negative with all sera tested. The Mi-2
antigen, present in the cell nucleus, appears to be a complex of proteins,
the most prominent of which is 220–240 kD, with additional components
of 30, 63, 65,75,150kD, and possibly others [73]. No nucleic acid is
known to be associated with the antigen. Nothing is known about the
cellular role of the Mi-2 antigen.
OTHER MSA
Unlike the MSA discussed above, each of which is found in a limited
number of patients, usually representing a clinically recognizable
subgroup, the anti–56-kD antibody has been reported to occur in all
groups of myositis patients, including both DM and PM, and both adults
and children [17]. Its titers tend to vary with disease activity. It was found
in 85% of 52 myositis patients, but in none of 11 patients with other
muscle diseases. However, it is not entirely myositis-specific, because
low levels of the antibody have been found in up to 10% of patients with
SLE or other conditions. The antibody is detected by immunoblot as a
56-kD protein of ribonu-cleoprotein particles isolated from Syrian
hamster cell nuclei [74]. Its relation to the other MSA is unclear.
Also reported to occur in myositis are antibodies to muscle-specific
proteins. Although many studies have failed to associate antibodies to
muscle proteins with myositis, a few have reported such antibodies
[75,76]. Wada et al reported antibodies to myosin in 90% of myositis
patients, without regard to clinical subgroup, that correlated with disease
activity [75]. As with anti-56 kD, these antibodies were also not
completely specific for myositis, being found in other muscle diseases,
but they were much more common and in higher titer in PM/DM. The
lack of disease or subgroup specificity raises the possibility that they are
secondary to muscle damage, which is much more likely with muscle-
specific antibodies than with MSA.
SIGNIFICANCE OF THE MSA
The MSA are clearly important in understanding myositis because of their
disease and subgroup specificity. An understanding of the origin of these
antibodies may provide insight into the cause and pathogenesis of PM/
DM. Production of these antibodies is influenced by the major
histocompatibility complex. Anti–Jo-1 is strongly associated with HLA
DR3 in white patients [77], although this association is not seen in black
patients. All anti-synthetases, antibodies to translation-related proteins,
and anti-SRP have been associated with HLA DRw52, in both black and
white patients [16,77]. This has been proposed as the important
association. Anti-PM-Scl is also very strongly associated with HLA DR3
[78], whereas anti-Mi-2 has been associated with HLA DR7 [16].
An unidentified factor working in the genetically susceptible
individual appears to be important in the generation of the MSA, which
may differ with different antibodies. As noted above, there is much
speculation that this factor is a virus that may be responsible for causing
the myositis. The production of the MSA may be one mechanism by
which the tissue damage develops, or the MSA may be an epipheno-
menon of a viral infection that may be responsible for induction of
myositis through other mechanisms. There is no direct evidence that the
antibodies are pathogenic, and the absence of antibody deposition in DM
skin lesions or PM muscle speaks against their role. Furthermore, it is
difficult conceptually to understand how these intracellular antigens can
be a primary target of attack.
However, certain considerations indicate that a possible role for these
antibodies warrants further study. First, there is a general correlation of
anti–Jo-1 titer and disease activity. This was found in at least two studies
[30,41], although not all studies agree. Improvement and especially
complete remission of disease seem to be associated consistently with a
fall in titer and occasionally with the disappearance of the antibody [41],
and the new appearance of antibody was followed by the development of
the disease [35]. A correlation of antibody titer has been found with
disease activity index and with creatine kinase level [41]. Anti–Jo-1 is
seldom found in the absence of myositis, and then usually in patients
with ILD. Anti-PL-7 has also been correlated with disease activity [79].
There is also a possibility that under some circumstances the
intracellular antigens of the MSA are expressed on the surface of muscle
or other cells, which might explain how either cell-mediated or humoral
attack directed at the antigens could contribute to tissue damage.
Although true MSA have not been demonstrated on cell surfaces, other
antigens, including Ro/SSA [80], ribosomal Po [81], and 70-kD Ku [82],
have been found to be expressed on the cell surface membrane under
some conditions. Such expression could conceivably be related to cell
insults such as viral infection. An additional possibility is that
autoantibodies enter cells under some circumstances, but the likelihood
of such a process occurring to a significant degree seems more difficult to
support.
FUTURE STUDIES
The future study of humoral immunity in myositis will pursue an
understanding of 1) the origin of the autoantibodies and their role in the
various manifestations of PM/DM, and 2) the mechanisms for small vessel
damage and local complement activation in DM. Further study of the
autoantibodies and their precise epitope patterns will be facilitated by the
availability of cloned antigens. As tests for the antibodies become more
widely available, their value in diagnosis and patient management will
be clarified. An understanding of the MSA will be important not only in
PM/DM but may bear on autoantibodies in other autoimmune disease.
Th is work was supported by grants AR-32214, Al-21181, and AI215 68 from the National
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